- Home
- EMF vs DRTS Comparison
EMF vs DRTS Comparison
Compare EMF & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- DRTS
- Stock Information
- Founded
- EMF 1987
- DRTS 2015
- Country
- EMF United States
- DRTS Israel
- Employees
- EMF N/A
- DRTS N/A
- Industry
- EMF Finance/Investors Services
- DRTS Medical/Dental Instruments
- Sector
- EMF Finance
- DRTS Health Care
- Exchange
- EMF Nasdaq
- DRTS Nasdaq
- Market Cap
- EMF 192.8M
- DRTS 159.1M
- IPO Year
- EMF N/A
- DRTS N/A
- Fundamental
- Price
- EMF $11.95
- DRTS $3.10
- Analyst Decision
- EMF
- DRTS Strong Buy
- Analyst Count
- EMF 0
- DRTS 2
- Target Price
- EMF N/A
- DRTS $8.00
- AVG Volume (30 Days)
- EMF 29.3K
- DRTS 62.8K
- Earning Date
- EMF 01-01-0001
- DRTS 11-19-2024
- Dividend Yield
- EMF 6.16%
- DRTS N/A
- EPS Growth
- EMF N/A
- DRTS N/A
- EPS
- EMF N/A
- DRTS N/A
- Revenue
- EMF N/A
- DRTS N/A
- Revenue This Year
- EMF N/A
- DRTS N/A
- Revenue Next Year
- EMF N/A
- DRTS N/A
- P/E Ratio
- EMF N/A
- DRTS N/A
- Revenue Growth
- EMF N/A
- DRTS N/A
- 52 Week Low
- EMF $10.58
- DRTS $1.75
- 52 Week High
- EMF $12.67
- DRTS $3.40
- Technical
- Relative Strength Index (RSI)
- EMF 33.30
- DRTS 74.53
- Support Level
- EMF $11.61
- DRTS $2.88
- Resistance Level
- EMF $13.14
- DRTS $3.20
- Average True Range (ATR)
- EMF 0.29
- DRTS 0.10
- MACD
- EMF -0.06
- DRTS 0.00
- Stochastic Oscillator
- EMF 27.66
- DRTS 81.25
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.